Senseonics Holdings (SENS) AI Stock Analysis

• Market Cap: $340.35M
• Dividend Yield: N/A
• Average Volume (3M): 442.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.81
• Revenue Growth: 31.94%
• EPS Growth: 36.59%
• Country: US
• Employees: 117
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.46
• Shares Outstanding: 40,858,460
• 10 Day Avg. Volume: 311,620
• 30 Day Avg. Volume: 442,917
• PEG Ratio: 0.10
• Price to Book (P/B): 3.77
• Price to Sales (P/S): 6.53
• P/FCF Ratio: -3.82
• Enterprise Value/Market Cap: 0.82
• Enterprise Value/Revenue: 7.94
• Enterprise Value/Gross Profit: 17.76
• Enterprise Value/Ebitda: -4.49
• 1Y Price Target: $18.70
• Price Target Upside: 124.49% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -2.39
• Revenue Forecast (FY): $60.24M

• Rating: 52 Neutral
• Price Target: $8.50 ▲(2.04% Upside)
• Action: Reiterated Date: 03/03/26
• Date: Action: Reiterated 03/03/26

The score is held back primarily by weak financial performance—large recurring losses and persistent negative free cash flow—despite improving revenue growth and margin trends. Technical indicators are constructive in the near term, and the earnings call includes strong growth guidance, but elevated planned 2026 spending and cash utilization meaningfully increase execution and funding risk.

Positive Factors

Revenue Growth and Commercial Traction

Sustained double-digit revenue acceleration and outsized U.S. patient/prescriber growth indicate product-market fit and scalable demand for Eversense. This expands the recurring consumable base and strengthens long-term revenue visibility if retention and prescriber adoption persist.

Material Margin Improvement

A durable shift to >50% gross margins reflects improved unit economics from commercialization changes and higher mix of in-house sales. Higher gross margins provide structural leverage to support future operating investments and the path to sustainable profitability as volumes scale.

Control of Commercialization & Strategic Partnerships

Bringing U.S. commercialization in-house and internalizing European revenues increases revenue capture and margin control while enabling direct DTC and provider strategies. Combined with CE mark and pump integrations, this strengthens go-to-market flexibility and long-term competitive positioning.

Negative Factors

High Near-Term Cash Burn

Planned 2026 cash burn materially exceeds year-end cash, raising execution and financing risk. Heavy near-term outflows increase probability of needing external funding, potentially dilutive or costly, and place pressure on management to convert commercial investment into faster revenue realization.

Persistent Negative Operating Cash Flow

Chronic negative operating and free cash flow signal the business is not self-funding and remains dependent on external capital. This structural cash deficit limits financial flexibility, elevates refinancing risk, and forces tradeoffs between growth investments and balance sheet conservation.

Large Planned Operating Expense Base

A sharply higher SG&A and operating expense run-rate creates execution risk: if revenue ramp or DTC efficiency lags, margins and liquidity will deteriorate. The heavy investment cadence raises the bar on operational execution and increases potential for extended unprofitability.

Senseonics Holdings Business Overview & Revenue Model

Company Description

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

How the Company Makes Money

Senseonics generates revenue primarily through the sale of its Eversense CGM systems, which include the implantable sensors, the associated applicators, and the mobile app. The company earns revenue from both product sales and recurring income from sensor replacements, as the sensors need to be replaced periodically. Key revenue streams include direct sales to healthcare providers, distribution agreements, and partnerships with diabetes care organizations. Additionally, Senseonics may benefit from strategic collaborations and agreements with larger healthcare firms, which can enhance market access and increase product adoption, further contributing to its earnings.

Senseonics Holdings Financial Statement Overview

Summary

Revenue growth re-accelerated and gross margin rebounded sharply in 2025, and leverage looks more manageable in the latest year. However, profitability remains deeply negative and operating/free cash flow are consistently negative, indicating ongoing cash burn and continued reliance on external funding.

Income Statement

Revenue growth re-accelerated in 2025 (up ~14% year over year) after being essentially flat in 2024, and gross margin improved sharply to ~45% in 2025 (from ~2% in 2024). However, profitability remains weak: 2023–2025 show deeply negative net margins (about -270% to -350% in 2023–2024 and ~-196% in 2025) with sizable operating losses, indicating the cost structure is still far ahead of the current revenue base. 2022 shows an outsized profit year, but results since then have reverted to heavy losses, reducing confidence in earnings consistency.

Balance Sheet

Leverage looks more manageable in 2025 with debt of ~$40.9M against equity of ~$61.0M (debt-to-equity ~0.67), and the company has a reasonable asset base (~$126.3M). That said, the balance sheet has been volatile: equity was negative in 2021, 2022, and 2024, which signals prior dilution/accumulated losses and increases financial risk. Returns on equity are currently negative (2025), consistent with ongoing losses.

Cash Flow

Cash generation remains the key pressure point. Operating cash flow is consistently negative (about -$56M to -$70M annually across 2020–2025), and free cash flow is also negative each year (about -$56M to -$71M), implying continued cash burn. While free cash flow improved modestly in 2025 versus 2024, the business still appears dependent on external funding until operating losses narrow materially.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	35.26M	22.47M	22.39M	16.39M	13.68M
Gross Profit	15.76M	533.00K	3.09M	2.73M	-811.00K
EBITDA	-68.34M	-68.70M	-48.01M	161.81M	-284.51M
Net Income	-69.11M	-78.62M	-60.39M	142.12M	-302.47M
Balance Sheet
Total Assets	126.27M	100.44M	138.22M	177.67M	198.93M
Cash, Cash Equivalents and Short-Term Investments	40.23M	74.60M	109.46M	144.01M	129.91M
Total Debt	40.88M	61.05M	47.78M	75.38M	64.21M
Total Liabilities	65.22M	116.99M	64.77M	180.25M	384.46M
Stockholders Equity	61.05M	-16.55M	73.45M	-2.58M	-185.53M
Cash Flow
Free Cash Flow	-60.24M	-62.70M	-70.51M	-66.62M	-56.29M
Operating Cash Flow	-59.13M	-60.47M	-70.16M	-66.31M	-56.08M
Investing Cash Flow	-53.42M	32.84M	89.71M	26.88M	-148.75M
Financing Cash Flow	78.19M	26.83M	20.37M	41.76M	220.08M

Senseonics Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.33
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SENS, the sentiment is Positive. The current price of 8.33 is above the 20-day moving average (MA) of 7.83, above the 50-day MA of 7.13, and below the 200-day MA of 8.46, indicating a neutral trend. The MACD of 0.33 indicates Negative momentum. The RSI at 62.74 is Neutral, neither overbought nor oversold. The STOCH value of 78.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SENS.

Senseonics Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DXCM	77 Outperform	$28.40B	35.25	34.50%	―	14.21%	5.66%
PODD	68 Neutral	$17.28B	70.11	18.12%	―	27.12%	-41.72%
LIVN	68 Neutral	$3.84B	-15.70	-19.24%	―	8.97%	-1024.86%
XTNT	66 Neutral	$80.00M	55.98	3.64%	―	16.88%	―
SENS	52 Neutral	$340.35M	-4.88	-129.29%	―	31.94%	36.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TNDM	45 Neutral	$1.72B	-8.22	-97.88%	―	17.87%	-57.03%

Senseonics Holdings Corporate Events

Senseonics Reports Record 2025 Revenue and Growth Milestones

On January 12, 2026, Senseonics reported preliminary unaudited revenue of approximately $14.2 million for the fourth quarter of 2025 and $35.2 million for full-year 2025, representing year-over-year growth of 71% and about 57% respectively and marking the highest quarterly and annual revenue in the company’s history. The company’s cash, cash equivalents and restricted cash were estimated at about $94.3 million as of December 31, 2025, while its U.S. patient base more than doubled in the fourth quarter, up 103% from a year earlier, driven largely by direct-to-consumer marketing; operationally, Senseonics advanced its pipeline with FDA IDE approval and first patient enrollment for the pivotal Gemini sensor trial, initiated commercial use of pump partner Sequel’s twiist insulin delivery system compatible with Eversense 365, and executed agreements for Ascensia Diabetes Care to assume U.S. commercialization and distribution of Eversense starting January 1, 2026, developments that collectively strengthen its competitive position in the CGM market.

The most recent analyst rating on (SENS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.

Senseonics Acquires Eversense U.S. Assets, Reshapes Partnership

On December 31, 2025, Senseonics Holdings and its subsidiary Senseonics, Inc. signed a master asset purchase agreement with Ascensia Diabetes Care Holdings to acquire certain U.S. assets related to the marketing, selling and distribution of the Eversense CGM product, with the U.S. asset purchase closing on January 1, 2026 for approximately $1.1 million in cash, along with the assumption of related liabilities, including transferred contracts and certain employees. The parties also plan, subject to local agreements and regulatory and contractual closing conditions, to acquire additional commercial Eversense assets in Italy, Germany, Spain and Sweden by June 30, 2026, while an amended and restated collaboration and commercialization agreement effective January 1, 2026 terminates Ascensia’s U.S. marketing rights, makes its European rights non-exclusive, and shifts 100% of Eversense revenues in Europe to Senseonics, marking a strategic move to internalize global commercial operations; concurrently, PHC Holdings executive Koichiro Sato resigned from Senseonics’ board, and PHC signaled it does not currently intend to designate a new director despite retaining the right to do so.

The most recent analyst rating on (SENS) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.